Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Bellerophon Therapeutics stock opened at $0.04 on Friday. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.10. The firm has a market capitalization of $452,621.00, a price-to-earnings ratio of -0.04 and a beta of 0.71. The firm has a 50 day moving average of $0.04 and a 200 day moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.